PATHOLOGICAL CLASSIFICATION AND CLINICAL SIGNIFICANCE OF BLADDER CANCER BASED ON MUTATION OF NUCLEAR ONCOGENE AND TUMOR SUPRESSOR GENE.

基于核癌基因和抑癌基因突变的膀胱癌病理分类及临床意义。

• 批准号: 06671604
• 负责人: NOGUCHI Sumio
• 金额: $ 0.9万
• 依托单位: YOKOHAMA CITY UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06671604/
• 关键词: NUCLEAR ONCOGENE; TUMOR SUPRESSOR GENE; BLADDER CANCER

We investigate the roles and possible interactions of retinoblastoma (RB), transforming growth factor-beta 1 (TGF-beta1) and c-myc genes in bladder cancer. The expression of these 3 genes was examined in 38 biopsy specimens of human bladder cancer by immunohistochemical study and Northern blotting. Loss of the retinoblastome protein expression was most significantly correlated with high grade cancer. Over expression of c-myc or expression of TGF-beta1 was less associated with tumor grade or stage, although c-myc over expression defined stage Ta against other stage tumors, since no stage Ta lesions had increased c-myc expression. Finally, loss of RB gene function did not correlate with either c-myc or TGF-beta1 expression.These results further support that RB gene inactivation is an important factor in the progression of bladder cancer, and suggest that TGF-beta1 and c-myc are not regulators or not regulated by RB gene expression.

我们研究了视网膜母细胞瘤 (RB)、转化生长因子-β 1 (TGF-β1) 和 c-myc 基因在膀胱癌中的作用和可能的相互作用。通过免疫组织化学研究和 Northern blotting 在 38 份人类膀胱癌活检标本中检测了这 3 个基因的表达。视网膜母细胞组蛋白表达的丧失与高级别癌症最显着相关。 c-myc 的过度表达或 TGF-β1 的表达与肿瘤分级或分期的相关性较小，尽管 c-myc 过度表达相对于其他阶段的肿瘤定义了 Ta 期，因为没有 Ta 期病灶增加了 c-myc 表达。最后，RB基因功能的丧失与c-myc或TGF-β1表达无关。这些结果进一步支持RB基因失活是膀胱癌进展的重要因素，并表明TGF-β1和c-myc不是调节因子或不受RB基因表达调节。

项目成果

Yoshinobu Kubota: "The Loss of Retinoblastoma Gene in Association with c-myc and TGF-β1 Gene expression in Human Bladder Cancer" The Journal of Urology. (in press). (1995)

Yoshinobu Kubota：“人类膀胱癌中视网膜母细胞瘤基因的丢失与 c-myc 和 TGF-β1 基因表达相关”，泌尿学杂志（1995 年出版）。

窪田吉信: "泌尿器科領域における癌遺伝子.癌抑制遺伝子" 臨床泌尿器科. 48. 185-194 (1994)

Yoshinobu Kubota：“泌尿外科领域的癌基因。肿瘤抑制基因”《临床泌尿外科》48。185-194（1994）

Miyamoto,H: "Analyses of P53 gene mutation in primary human bladder cancer" Oncology Research. 5. 245-249 (1993)

Miyamoto,H：“原发性人类膀胱癌 P53 基因突变分析”肿瘤学研究。

Miyamoto, H., Kubota, Y., Shuin, T., Torigoe, S., Hosaka, M., Iwasaki, Y., Danenberg, K.and Danenberg, P.: "Analysisof p53 mutation inprimary human bladder cancer." Oncology Research. 5. 245-249 (1993)

Miyamoto, H.、Kubota, Y.、Shuin, T.、Torigoe, S.、Hosaka, M.、Iwasaki, Y.、Danenberg, K. 和 Danenberg, P.：“原发性人类膀胱癌中 p53 突变的分析。”

Kubota,Y: "The loss of retinoblastoma gene in association with c-myc and transforming growth factor-β1gene expression in human bladder cancer" The Journal of Urology. 154. 371-374 (1995)

Kubota, Y：“人类膀胱癌中与 c-myc 和转化生长因子-β1 基因表达相关的视网膜母细胞瘤基因的丢失”《泌尿学杂志》154. 371-374 (1995)。